HemaSphere is the official online, open access journal of the European Hematology Association (EHA). HemaSphere publishes exciting basic, translational, and clinical research in hematology. We are pleased to introduce our new podcast series where our host and guest speakers exchange ideas about select HemaSphere publications. Spend some time with us and enjoy casual and insightful discussions about hematology research. Whether or not you have read the publications, now hear the stories. Hema ...
…
continue reading
Authors of this recent HemaSphere published paper discovered a high-risk subgroup of pediatric T-LBL, defined by NOTCH1 gene fusions. This finding will have an important impact on newly diagnosed children with T-LBL globally, listen to two of the co-authors, Dr Jan Loeffen and Professor Roland Kuipers discuss their findings with Dr Charles de Bock,…
…
continue reading
1
A transcriptional cofactor‐mediated dependency module
24:48
24:48
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
24:48
In this newest podcast episode, Dr Charles de Bock hosts Dr Thomas Mercher and Dr Alexandre Fagnan. This episode is based on their recent paper, “The ETO2 transcriptional co-factor maintains acute leukemia by driving a MYB/EP300-dependent stemness program”, highlighting ETO2 activated gene transcription and how this affects erythroleukemia. The dis…
…
continue reading
1
Unraveling the secrets of thrombopoiesis
25:20
25:20
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
25:20
Welcome to Season 2 of our podcast! In this episode, Dr. Francesca Vinchi interviews Professor Alessandra Balduini about thrombopoiesis. They explore Prof. Balduini's journey into research, her intuition that led to silk scaffolding, and her hopes on future results. "Unraveling the secrets of thrombopoiesis", is on our website and all major podcast…
…
continue reading
1
What’s so Great About the P-value? A Statistician’s Point of View
30:24
30:24
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
30:24
Dr Stephen Hibbs invites HemaSphere Associate Editor Prof Robert K Hills to discuss statistics in scientific writing in an entertaining and informative episode: What’s so Great About the P-value? A Statistician’s Point of View. This discussion covers the overlap of statistics and hematology with themes like the importance of P value and the use of …
…
continue reading
1
This Is Going to Hurt: Revisiting the Patient Experience of Bone Marrow Biopsies
24:16
24:16
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
24:16
Dr Stephen Hibbs invites Dr Joseph Taylor to a discussion based on Dr Hibbs popular HemaTopics article, This Is Going to Hurt: Revisiting the Patient Experience of Bone Marrow Biopsies. The conversation ranges from the type of training providers receive, how to talk to patients about these bone marrow biopsies, and some of the outstanding questions…
…
continue reading
1
The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children
27:29
27:29
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
27:29
Though many advances have been made in neutropenias, diagnosis and management are still based on physicians’ experience or local practices. Prof Francesca Fioredda and Prof Helen Papadaki, two co-authors of the HemaSphere published article The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between…
…
continue reading
1
Part 1 - Comprehensive Diagnosis and Management of POEMS Syndrome
23:23
23:23
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
23:23
POEMS syndrome (Polyneuropathy Organomegaly, Endocrinopathy, M-protein and Skin changes) is rare, and systemic manifestations are commonly overlooked initially. Diagnosis is often delayed 12-16 months, during which patients can be severely disabled. No established treatment guidelines exist for POEMS. A recent HemaSphere published article, Comprehe…
…
continue reading
1
Part 2 - Comprehensive Diagnosis and Management of POEMS Syndrome
24:32
24:32
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
24:32
POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, M-protein and Skin changes) is rare, and systemic manifestations are commonly overlooked initially. Diagnosis is often delayed 12-16 months, during which patients can be severely disabled. No established treatment guidelines exist for POEMS. A recent HemaSphere published article Comprehe…
…
continue reading
1
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
34:01
34:01
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
34:01
Machine Learning is a subsection in the field of Artificial Intelligence. How can this be used as a tool in hematology-oncology for advanced disease prognostification and beyond? Adrián Mosquera-Orgueira and Juan Carlos Hernández-Boluda, two co-authors of the HemaSphere published article Machine Learning Improves Risk Stratification in Myelofibrosi…
…
continue reading
1
EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer
24:32
24:32
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
24:32
As the overall cancer death rate has declined over past decades and cancer survival has increased, unforeseen challenges are emerging. Thrombocytopenia, often associated with cancer disease or anticancer therapy, will be more present in thrombotic cancer patients, but evidence on how to treat these patients is lacking. Prof Anna Falanga discusses t…
…
continue reading
1
“Long COVID-19” of Researchers: What to Do Next?
20:07
20:07
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
20:07
What to do next for “Long COVID-19” of researchers? A survey from scientists to scientists led by the Young European Hematology Association (Young EHA)committee led to this discussion about how COVID-19 impacted researchers, especially earlier in their career and without a network. What tools did they discover to get through it? Find it on the Hema…
…
continue reading